MedTrace Logo

Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease

NCT07294586 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-12-19

No results posted yet for this study

Summary

This is a 24-month, monocentric, exploratory and observational clinical study aimed at developing and validating a blood-based diagnostic test for Alzheimer's disease (AD). The test is based on two complementary biomarkers: conformational changes in Protein Kinase C (PKC) and aggregation of β-amyloid peptide on red blood cell membranes. The study will also establish a biobank of serum, plasma, urine, and RNA samples for future biomarker research.

Conditions

Sponsors & Collaborators

  • Hopitaux Civils de Colmar

    collaborator OTHER

  • Amoneta Diagnostics SAS

    lead INDUSTRY

Principal Investigators

  • François Sellal, MD · Hopitaux Civils de Colmar

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-28
Primary Completion
2019-10-28
Completion
2021-06-24

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07294586 on ClinicalTrials.gov